Suppr超能文献

血管紧张素转换酶(ACE)抑制剂对原发性高血压的降压疗效。

Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.

作者信息

Heran Balraj S, Wong Michelle My, Heran Inderjit K, Wright James M

机构信息

Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Sciences Mall, Vancouver, British Columbia, Canada, V6T 1Z3.

出版信息

Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD003823. doi: 10.1002/14651858.CD003823.pub2.

Abstract

BACKGROUND

ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure (BP), heart rate and withdrawals due to adverse effects (WDAE).

OBJECTIVES

To quantify the dose-related systolic and/or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension.

SEARCH STRATEGY

We searched CENTRAL (The Cochrane Library 2007, Issue 1), MEDLINE (1966 to February 2007), EMBASE (1988 to February 2007) and reference lists of articles.

SELECTION CRITERIA

Double-blind, randomized, controlled trials evaluating the BP lowering efficacy of fixed-dose monotherapy with an ACE inhibitor compared with placebo for a duration of 3 to 12 weeks in patients with primary hypertension.

DATA COLLECTION AND ANALYSIS

Two authors independently assessed the risk of bias and extracted data. Study authors were contacted for additional information. WDAE information was collected from the trials.

MAIN RESULTS

Ninety two trials evaluated the dose-related trough BP lowering efficacy of 14 different ACE inhibitors in 12 954 participants with a baseline BP of 157/101 mm Hg. The data do not suggest that any one ACE inhibitor is better or worse at lowering BP. A dose of 1/8 or 1/4 of the manufacturer's maximum recommended daily dose (Max) achieved a BP lowering effect that was 60 to 70% of the BP lowering effect of Max. A dose of 1/2 Max achieved a BP lowering effect that was 90% of Max. ACE inhibitor doses above Max did not significantly lower BP more than Max. Combining the effects of 1/2 Max and higher doses gives an estimate of the average trough BP lowering efficacy for ACE inhibitors as a class of drugs of -8 mm Hg for SBP and -5 mm Hg for DBP. ACE inhibitors reduced BP measured 1 to 12 hours after the dose by about 11/6 mm Hg.

AUTHORS' CONCLUSIONS: There are no clinically meaningful BP lowering differences between different ACE inhibitors. The BP lowering effect of ACE inhibitors is modest; the magnitude of trough BP lowering at one-half the manufacturers' maximum recommended dose and above is -8/-5 mm Hg. Furthermore, 60 to 70% of this trough BP lowering effect occurs with recommended starting doses. The review did not provide a good estimate of the incidence of harms associated with ACE inhibitors because of the short duration of the trials and the lack of reporting of adverse effects in many of the trials.

摘要

背景

血管紧张素转换酶(ACE)抑制剂被广泛用于治疗高血压,因此确定并比较其对血压(BP)、心率及因不良反应导致停药(WDAE)的影响至关重要。

目的

量化ACE抑制剂与安慰剂相比在治疗原发性高血压时与剂量相关的收缩压和/或舒张压降低疗效。

检索策略

我们检索了Cochrane中心对照试验注册库(CENTRAL,《Cochrane图书馆》2007年第1期)、医学索引数据库(MEDLINE,1966年至2007年2月)、荷兰医学文摘数据库(EMBASE,1988年至2007年2月)以及文章的参考文献列表。

选择标准

双盲、随机、对照试验,评估固定剂量单一疗法使用ACE抑制剂与安慰剂相比在原发性高血压患者中持续3至12周的降压疗效。

数据收集与分析

两位作者独立评估偏倚风险并提取数据。联系研究作者获取更多信息。从试验中收集WDAE信息。

主要结果

92项试验评估了14种不同ACE抑制剂在12954名基线血压为157/101 mmHg的参与者中与剂量相关的心衰血压降低疗效。数据并不表明任何一种ACE抑制剂在降低血压方面更好或更差。制造商最大推荐日剂量(Max)的1/8或1/4剂量所产生的降压效果为Max降压效果的60%至70%。1/2 Max剂量所产生的降压效果为Max的90%。高于Max的ACE抑制剂剂量在降低血压方面并不比Max显著更有效。将1/2 Max及更高剂量的效果综合起来估计,ACE抑制剂作为一类药物的平均谷值血压降低疗效为收缩压-8 mmHg,舒张压-5 mmHg。ACE抑制剂在给药后1至12小时测量的血压降低约11/6 mmHg。

作者结论

不同ACE抑制剂之间在临床上没有有意义的降压差异。ACE抑制剂的降压效果适中;在制造商最大推荐剂量的一半及以上时,谷值血压降低幅度为-8/-5 mmHg。此外,这种谷值血压降低效果的60%至70%出现在推荐起始剂量时。由于试验持续时间短且许多试验未报告不良反应,本综述未能很好地估计与ACE抑制剂相关的危害发生率。

相似文献

1
Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.
Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD003823. doi: 10.1002/14651858.CD003823.pub2.
2
Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension.
Cochrane Database Syst Rev. 2008 Oct 8;2008(4):CD003822. doi: 10.1002/14651858.CD003822.pub2.
3
Blood pressure lowering efficacy of renin inhibitors for primary hypertension.
Cochrane Database Syst Rev. 2017 Apr 5;4(4):CD007066. doi: 10.1002/14651858.CD007066.pub3.
4
Blood pressure lowering efficacy of alpha blockers for primary hypertension.
Cochrane Database Syst Rev. 2009 Oct 7(4):CD004643. doi: 10.1002/14651858.CD004643.pub2.
5
Blood pressure lowering efficacy of diuretics as second-line therapy for primary hypertension.
Cochrane Database Syst Rev. 2009 Oct 7(4):CD007187. doi: 10.1002/14651858.CD007187.pub2.
6
First-line drugs for hypertension.
Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD001841. doi: 10.1002/14651858.CD001841.pub3.
7
Eplerenone for hypertension.
Cochrane Database Syst Rev. 2017 Feb 28;2(2):CD008996. doi: 10.1002/14651858.CD008996.pub2.
8
Blood pressure lowering efficacy of renin inhibitors for primary hypertension.
Cochrane Database Syst Rev. 2008 Oct 8(4):CD007066. doi: 10.1002/14651858.CD007066.pub2.
9
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
10
Blood pressure lowering efficacy of loop diuretics for primary hypertension.
Cochrane Database Syst Rev. 2009 Oct 7(4):CD003825. doi: 10.1002/14651858.CD003825.pub2.

引用本文的文献

2
Pharmacogenomics and its Role in Cardiovascular Diseases: A Narrative Literature Review.
Curr Cardiol Rev. 2025;21(4):e1573403X334668. doi: 10.2174/011573403X334668241227074314.
5
Impact of expected blood pressure reduction on patient preferences for pharmaceutical and renal denervation treatment.
J Hypertens. 2025 Feb 1;43(2):228-235. doi: 10.1097/HJH.0000000000003872. Epub 2024 Sep 26.
8
Causal linkage between angiotensin-converting enzyme 2 and risk of lung cancer: a bidirectional two-sample Mendelian randomization study.
Front Med (Lausanne). 2024 Jul 8;11:1419612. doi: 10.3389/fmed.2024.1419612. eCollection 2024.
10
Effect of the DASH diet on the sodium-chloride cotransporter and aquaporin-2 in urinary extracellular vesicles.
Am J Physiol Renal Physiol. 2024 Jun 1;326(6):F971-F980. doi: 10.1152/ajprenal.00274.2023. Epub 2024 Apr 18.

本文引用的文献

1
Post-exercise reduction in blood pressure in hypertensive subjects: effects of angiotensin converting enzyme inhibition.
Br J Clin Pharmacol. 1993 Oct;36(4):331-8. doi: 10.1111/j.1365-2125.1993.tb00372.x.
9
T-lymphocyte and plasma angiotensin-converting enzyme activity during enalapril and losartan administration in humans.
J Cardiovasc Pharmacol. 2001 Oct;38(4):578-83. doi: 10.1097/00005344-200110000-00010.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验